Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
1. A method comprising:
a) testing nucleic acid from a human for a polymorphism in gene ATF6 as represented by position 101 of SEQ ID NO:19038 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to C at said position 101 of SEQ ID NO:19038 or G at said complement;
b) detecting said C or said G;
c) identifying said human as having an increased risk for myocardial infarction due to the presence of said C or said G; and
d) administering a therapeutic agent suitable for prevention or treatment of myocardial infarction to said human.
2. The method of claim 1 , wherein said testing comprises amplifying by polymerase chain reaction (PCR) a fragment of said nucleic acid that includes said position 101 of SEQ ID NO:19038 or its complement to thereby create an amplicon containing said position, and contacting said amplicon with said oligonucleotide.
3. The method of claim 1 , wherein said method comprises preparing a sample from said human that is enriched for a fragment of said nucleic acid that includes said position 101 of SEQ ID NO: 19038 or its complement by amplifying said fragment by polymerase chain reaction (PCR).
4. The method of claim 1 , wherein the nucleotide sequence of said oligonucleotide consists of a segment of at least 12 contiguous nucleotides of SEQ ID NO:19038 or its complement and includes said position 101.
5. The method of claim 1 , wherein said oligonucleotide is an allele-specific probe.
6. The method of claim 1 , wherein said oligonucleotide is detectably labeled.
7. The method of claim 6 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.
8. The method of claim 1 , wherein said human is homozygous for said C or said G.
9. The method of claim 1 , wherein said human is heterozygous for said C or said G.
10. A method comprising:
a) testing nucleic acid from a human for a polymorphism in gene ATF6 as represented by position 101 of SEQ ID NO:19038 or its complement by contacting said nucleic acid with an allele-specific primer that specifically hybridizes to C at said position 101 of SEQ ID NO:19038 or G at said complement;
b) detecting said C or said G;
c) identifying said human as having an increased risk for myocardial infarction due to the presence of said C or said G; and
d) administering a therapeutic agent suitable for prevention or treatment of myocardial infarction to said human.
11. The method of claim 10 , wherein said detecting comprises detecting the presence of an amplicon.
12. The method of claim 10 , wherein said method comprises preparing a sample from said human that is enriched for a fragment of said nucleic acid that includes said position 101 of SEQ ID NO: 19038 or its complement by amplifying said fragment by polymerase chain reaction (PCR) using said allele specific primer.
13. The method of claim 10 , wherein said allele-specific primer comprises SEQ ID NO:73557.
14. The method of claim 10 , wherein said allele-specific primer is detectably labeled.
15. The method of claim 14 , wherein said allele-specific primer is detectably labeled with a fluorescent dye.
16. The method of claim 10 , wherein said human is homozygous for said C or said G.
17. The method of claim 10 , wherein said human is heterozygous for said C or said G.